Research School of Biology, Australian National University, Canberra, Australia.
Eskitis Institute for Drug Discovery, Griffith University, Brisbane, Australia.
Antimicrob Agents Chemother. 2018 May 25;62(6). doi: 10.1128/AAC.00087-18. Print 2018 Jun.
For an increasing number of antimalarial agents identified in high-throughput phenotypic screens, there is evidence that they target PfATP4, a putative Na efflux transporter on the plasma membrane of the human malaria parasite For several such "PfATP4-associated" compounds, it has been noted that their addition to parasitized erythrocytes results in cell swelling. Here we show that six structurally diverse PfATP4-associated compounds, including the clinical candidate KAE609 (cipargamin), induce swelling of both isolated blood-stage parasites and intact parasitized erythrocytes. The swelling of isolated parasites is dependent on the presence of Na in the external environment and may be attributed to the osmotic consequences of Na uptake. The swelling of the parasitized erythrocyte results in an increase in its osmotic fragility. Countering cell swelling by increasing the osmolarity of the extracellular medium reduces the antiplasmodial efficacy of PfATP4-associated compounds, consistent with cell swelling playing a role in the antimalarial activity of this class of compounds.
对于在高通量表型筛选中鉴定出的越来越多的抗疟药物,有证据表明它们的作用靶点是 PfATP4,这是人类疟原虫质膜上的一种假定的 Na 外排转运蛋白。对于几种这样的“PfATP4 相关”化合物,人们注意到它们被添加到寄生的红细胞中会导致细胞肿胀。在这里,我们表明,六种结构不同的 PfATP4 相关化合物,包括临床候选药物 KAE609(西普加民),会诱导分离的血期寄生虫和完整的寄生红细胞肿胀。分离寄生虫的肿胀依赖于外部环境中 Na 的存在,可能归因于 Na 摄取的渗透后果。寄生红细胞的肿胀导致其渗透脆性增加。通过增加细胞外介质的渗透压来对抗细胞肿胀,会降低 PfATP4 相关化合物的抗疟效果,这与细胞肿胀在这类化合物的抗疟活性中发挥作用一致。